No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina / NY / Florida       

Ancora Heart and egnite, Inc. Announce Strategic Partnership to Accelerate Clinical Trial Enrollment for Heart Failure Patients

Use of artificial intelligence technology efficiently identifies eligible patient candidates for pivotal clinical trial; program launched at The Christ Health Network

What To Know

  • , a leading digital health company in the field of cardiovascular care, today announced a strategic partnership to accelerate clinical trial enrollment for Ancora Heart's CORCINCH-HF pivotal clinical trial, which is evaluating the safety and efficacy of the AccuCinch® Ventricular Restoration System.
  • “Our goal with the development of the AccuCinch System is to provide a minimally invasive treatment option to further improve the lives of heart failure patients whose symptoms progress despite guideline directed medical therapy,” said Mark Miles, chief commercial officer of Ancora Heart.

Ancora Heart, Inc., a medical device company developing a novel transcatheter device-based therapy to address heart failure (HF), and egnite, Inc., a leading digital health company in the field of cardiovascular care, today announced a strategic partnership to accelerate clinical trial enrollment for Ancora Heart’s CORCINCH-HF pivotal clinical trial, which is evaluating the safety and efficacy of the AccuCinch® Ventricular Restoration System. The partnership brings together the cutting-edge technology and expertise of both organizations with the goal of delivering innovative therapies to patients faster. The Christ Health Network in Cincinnati, OH is the first site in Ancora Heart’s CORCINCH-HF trial to utilize egnite’s Trial Accelerator artificial intelligence (AI) technology to help identify eligible patients.

“Our goal with the development of the AccuCinch System is to provide a minimally invasive treatment option to further improve the lives of heart failure patients whose symptoms progress despite guideline directed medical therapy,” said Mark Miles, chief commercial officer of Ancora Heart. “This partnership with egnite and The Christ Health Network will allow us to deploy AI tools such as egnite’s Trial Accelerator and expedite identification of eligible candidates for the CORCINCH-HF trial.”

egnite’s Trial Accelerator technology will also be leveraged at other participating CORCINCH-HF sites to drive patient identification and enrollment for the pivotal trial. The innovative solution can accelerate clinical trial enrollment through AI and big data processing, automatically screening hundreds of thousands of patients against trial parameters to help identify more trial candidates without hospital staff dedicating hours to manual chart review.

“Identifying patient candidates for clinical trial participation can be a complex task that requires many hours to review medical charts in the search for matching clinical criteria,” said Dr. Dean Kereiakes, president of The Christ Hospital Heart and Vascular Institute and co-principal investigator for CORCINCH-HF. “The use of AI technology streamlines the trial screening process by identifying candidates more quickly and efficiently, thereby freeing up critical resources needed for clinical trial success.”

“We are thrilled to partner with leading life sciences organizations like Ancora Heart and apply our novel technology to accelerate clinical trial enrollment,” said Joel Portice, president and chief executive officer of egnite. “We believe this collaboration is a significant step forward for patients and are excited to be at the forefront of cardiovascular care.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More

Advertise wiith Medical Device News Magazine

By using this website you agree to accept Medical Device News Magazine Privacy Policy